



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. JJPR-0027/ORT-1462	Application No. 09/921,516
	Applicant Loretta Itri, et al.	
	Filing Date August 1, 2001	Group 1642
	Confirmation No. 6089	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	73	Camma, C. et al., "The Effect of Interferon on the Liver in Chronic Hepatitis C : A Quantitative Evaluation of Histology by Meta-Analysis", <i>Journal of Hepatology</i> , 1997, 26, 1187-1199
	74	Demetri, G.D. et al., "Quality-of-Life Benefit in Chemotherapy Patients Treated with Epoetin Alfa is Independent of Disease Response or Tumor Type: Results from a Prospective Community Oncology Study", <i>Journal of Clinical Oncology</i> , 1998, 16(10), 3412-3425
	75	Kakizaki, S. et al., "Evaluation of Twice-Daily Administration of Interferon- β for Chronic Hepatitis C", <i>Journal of Viral Hepatitis</i> , 1999, 6, 315-319
	76	Lavezzo, B. et al., "Treatment of Recurrent Hepatitis C in Liver Transplants: Efficacy of a Six Versus a Twelve Month Course of Interferon alfa 2b with Ribavirin", <i>Journal of Hepatology</i> , 2002, 37, 247-252
	77	Maddrey, W.C. Md., "Safety of Combination Interferon alfa-2b/Ribavirin Therapy in Chronic Hepatitis C-Relapsed and Treatment-Naive Patients", <i>Seminars in Liver Disease</i> , 1999, 19(1), 67-75
	78	Miles, S.A., "The Use of Hematopoietic Growth Factors in HIV Infection and Aids-Related Malignancies Cancer Investigation", 1991, 9(2), 229-238
	79	Poynard, T. et al., "Randomised Trial of Interferon α 2b Plus Ribavirin for 48 Weeks or for 24 Weeks Versus Interferon α 2b Plus Placebo for 48 Weeks for Treatment of Chronic Infection with Hepatitis C Virus", <i>The Lancet</i> , 1998, 352, 1426-1432
	80	Weisz, K.B. et al., "Erythropoietin Use for Ribavirin/Interferon Induced Anemia in Patients with Hepatitis C", <i>Hepatology</i> , October 1998, 28(4), 288A, XP009031718
	81	Wolchok, J. et al., "Prophylactic Recombinant Epoetin Alfa Markedly Reduces the Need for Blood Transfusion in Patients with Metastatic Melanoma Treated with Biochemotherapy", <i>Cytokines Cellular and Molecular Therapy</i> , December 1999, 5(4), 205-206
✓	82	Interaction between α -Interferon and Erythropoietin in Antiviral and Antineoplastic Therapy in Uraemic Patients on Haemodialysis", <i>Nephron Dial. Transplant</i> , 1993, 8(11), 1308

Loretta Itri 8/22/2005



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. JJPR-0027/ORT-1462	Application No. 09/921,516
	Applicant Loretta Itri, et al.	
	Filing Date August 1, 2001	Group 1642
	Confirmation No. 6089	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
KAC	83	6,172,046 B1	01/09/01	Albrecht	514	43
	84	6,268,336 B1	07/31/01	Niitsu, et al.	514	8
	85	6,299,872 B1	10/09/01	Albrecht, et al.	424	85.7
	86	6,387,365 B1	05/14/02	Albrecht, et al.	424	85.4
	87	6,403,564 B1	06/11/02	Ganguly, et al.	514	43
	88	6,461,605 B1	10/08/02	Cutler, et al.	424	85.7
	89	6,472,373 B1	10/29/02	Albrecht	514	43
	90	6,673,775 B2	01/06/04	Ganguly, et al.	514	43

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
KAC	91	WO 98/19670	05/14/98	PCT		

EXAMINER

DATE CONSIDERED

8/22/2005